Ascidian Therapeutics

Focus: Ascidian Therapeutics is a Boston-based biotechnology company focused on mutated exon replacement therapy, currently in early-stage clinical development with a single program targeting rare genetic diseases.

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Open Jobs

About Ascidian Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Ascidian Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ACDN-01

Stargardt Disease

Phase 1/2

Clinical Trials (2)

NCT06467344Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Phase 1/2

Help build intelligence for Ascidian Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused expertise in novel mutated exon replacement platform—a differentiated modality with limited competitive landscape
Ground-floor opportunity at early-stage biotech where individual contributions directly shape clinical strategy and company trajectory
Targeting high-unmet-need rare disease (Stargardt Disease), positioning for potential orphan drug designation and accelerated regulatory pathways

Watch Out For

Only 2 active trials (Phase 1/2) with no Phase 3 programs—long timeline to meaningful commercial validation or exit
Pre-revenue status with unfunded stage and funding details unavailable—significant execution and capital sustainability risk
Zero published research output and no hiring currently active—suggests minimal team expansion or commercial momentum

Generated by Claude from Ascidian Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06445322Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

2 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles